# Sinopharm

Sinopharm’s Shopping Spree: Can M&A Cure the Giant’s Growing Pains?

Sinopharm Group is attempting to offset a stagnation in its core distribution business through a 10-billion-RMB acquisition spree in the diagnostics and blood-product sectors. However, the group faces significant hurdles, including high debt, internal competition among its 1,700 subsidiaries, and the ongoing pressure of China's centralized drug procurement policies.